http://www.globalwatchservice.com/pages/TwoColumns.aspx?PageID=439&ProfileID=1010&UseRef=False

Heres a recommendation from Hoods mind you since then ERX has had a bit of dilution, but i would not say no to 7.75p

http://www.eirx.com


AUDIO INTERVIEW
http://www.wallstreetreporter.com/interview.php?id=18589&player=wma


MGI Pharma
----------
http://www.eirx.com/eirx_heading_images/Vaccine%20Antigens%20v2.0.pdf#search=%22mgi%20pharma%20zyc300%22

http://www.mgipharma.com/


Current Patents:-
----------------
http://v3.espacenet.com/results?sf=a&FIRST=1&CY=gb&LG=en&DB=EPODOC&TI=&AB=&PN=&AP=&PR=&PD=&PA=eirx&IN=&EC=&IC=&=&=&=&=&=

http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006037993&F=0

http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP1601969&F=0


VERY DETAILED INDEPTH PRESENTATION PDF. All you need to know about EiRX.
------------------------------------------------------------------------
http://www.eirx.com/eirx_heading_images/EiRx%20-%20EPIC%20220606.pdf


Market research report: -
------------------------
http://www.marketresearch.com/product/display.asp?productid=1320831&g=1


EiRX Exhibiting & or Presenting
-------------------------------

Bio-Japan- September 06
http://expo.nikkeibp.co.jp/biojapan/2006/eng/report004.html

Boston US- October 06
http://www.discoveryontarget.com/06-RNAI.asp

I assume it is Jerry Adams from item 20 of 24 on page 1 that is the good news?

anyone any opion on why the 10% drop today?

bad news on pharma.. thats what.. to do with share options.. was nothing to do with us, but it effected almost all the sp's

raving

8p I think i saw a flying elephant ??

Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers
Phase II trials initiated
Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.

Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.

"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.

Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly interested in this tumour type because a large proportion harbour B-Raf mutations, and tumours with these mutations may be highly sensitive to MEK inhibitors.

The patients were randomised to receive 100 or 200mg doses, twice a day for 28-day cycles. The larger dose proved to be too high for continuous dosing due to adverse side effects, but the smaller dose was well tolerated over a prolonged period.

The researchers tested biopsy tissue taken from the patients both before and after dosing. They found that the pERK protein was reduced by 77%. They also looked at another protein, Ki-67, which is used as a marker for cell proliferation. After dosing, there was a reduction in Ki-67 in nine out of 20 patients, and in five of those nine patients the reduction was at least 50% or more.

"We found that after 15 days of dosing, AZD6244 continued to inhibit pERK at times when concentrations of the drug in the blood were at their lowest levels between doses. At the lowest concentration, 400 nanograms of the compound per microlitre of plasma still corresponded to a 35-44% inhibition of pERK," said Prof Adjei.

Overall, 39 of 57 patients completed at least one cycle of treatment with AZD6244. After completion of the second cycle, 19 (49%) had stable disease, and nine of these patients (six melanoma, one each of breast cancer, non-small cell lung cancer and medullary thyroid cancer) remained stable for five or more months (range, 5-14+ months; median, 6 months). Two patients, one with thyroid cancer and the other with melanoma, continue to receive treatment with AZD6244 after one year. Sixteen of the 20 patients with melanoma completed at least one cycle of treatment. Twelve had stable disease after completion of cycle two, with stable disease persisting for at least five months in six patients (range, 5 - 13+ months; median, 6.5 months).

Prof Adjei said: "This drug shows initial promising results. It appears to be able to target cancers with over-activation of MEK and associated cell signalling pathways in an efficient manner. Furthermore, it is easy to give to patients as it comes in an oral formulation that can be swallowed. As a result, a number of phase II clinical trials have been initiated in patients with melanoma, pancreatic, lung and colon cancers."

###
Embargoed: 12.30 hrs CET Wednesday 8 November 2006

Abstract no: 26

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research]. [2] AZD6244 (ARRY-142886), an MEK inhibitor, was invented by Array BioPharma and is being co-developed with AstraZeneca. Array BioPharma sponsored Prof Adjei's study.

Despite of 'Spudheads' ramping, ERX are owed monies from companies using thier patents, should be rerated soon.

I know... master. I have enough emails saying they are chasing the money..

so it should be with us pretty darned soon

up up and away

up and away again

Are you talking about your self again PH ! ;)

NEWS FLASH!!!!! - HOODS ON THE RUN

So PH when will the news be ref payments

the fact is, I heard that these are in the shares mag tomorrow.. thats why the rise..

From who PH AND No porkies

http://www.scottish-enterprise.com/sedotcom_home/news-se/news-fullarticle.htm?articleid=192953

DATE: 24/Jan/2006

Ten of Scotlands leading companies and universities specialising in oncology research and development are participating in a trade mission to Massachusetts to develop closer links with global pharmaceutical companies based in the region.


The trip, which has been co-ordinated by Scottish Development Internationals life sciences team, will enable participants to meet with the US-based companies and identify how the work of Scottish based universities and companies could help advance the work of these companies in developing new treatments for cancer related illnesses.


Massachusetts has one of the largest concentrations of life sciences companies in the world with more than 280 companies and 30,000 employees working in the sector and an internationally renowned academic base. The Scottish delegation will be meeting some of the worlds leading pharmaceutical and biotechnology companies including Pfizer, Amgen and Genzyme to help open up new business opportunities.


The US companies will learn about Scotlands leading oncology centres of excellence, including the recently opened Beatson Institute at the University of Glasgows Garscube Estate and the University of Edinburghs Cancer Research Centre, which has been developed in partnership with Cancer Research UK. Leading Scottish companies such as Cyclacel Pharmaceuticals, CXR Biosciences and EiRx Therapeutics will also be attending to identify potential collaborative opportunities with the US-based firms.


Ian Leslie, team leader of the Scottish Development International Life Sciences team says: Boston and the wider Massachusetts state is regarded as one of the worlds leading life sciences locations and home to some of the worlds biggest pharmaceutical and biotech companies. Scotlands world class reputation in the oncology field has helped us get the foot in the door with these global firms and this trip will be hugely important in promoting Scotlands strengths in oncology research and developing new opportunities for collaborative working and new business opportunities for Scottish based organisations.


Scottish Biomedical, a drug discovery services company based in Glasgow, is one of the companies participating and hopes the trip will lead to developing new relationships overseas.


Simon Bury, Business Development Director of Scottish Biomedical, says: The US is obviously a very lucrative market for life sciences and Massachussets is a key market to target. This trip is enabling us to meet with a number of global companies and hopefully develop new relationships to capitalise on our existing contacts overseas.


Oncology is one of Scotlands leading areas of life sciences research and one which has significant commercial potential. There are almost fifty major research groups, centre of excellence and departments within eight Scottish Universities and Research Institutes, working to understand the causes of different cancers and developing new treatments. There is also a growing base of companies actively looking at drug discovery and development to develop new cancer therapeutics.


The full list of organisations participating in the trade mission are: Accuro Biologics Ltd; CXR Biosciences; Cyclacel Pharmaceuticals; EiRx Therapeutics PLC; Nexus Oncology; Scottish Biomedical; University of Aberdeen; University of Dundee; University of Edinburgh and University of Glasgow.

http://www.biologynews.net/archives/2007/01/24/reactivated_gene_shrinks_tumors.html

READ THIS LINK.. WHY THE HELL IS THE SHARE PRICE THIS LOW, WE ARE WORTH 100'S OF MILLIONS.. ALL THIS INFO ON P53, THIS ARTICLE STATES 100% REDUCTION IN TUMOURS.. AND WE ARE AT THE FOREFRONT OF THIS.

There is no mention of ERX in your link, unless they are hiding behind the name of Massachusetts Institute of technology.